{"prompt": "['vitro diagnostic assay(s) related to emicizumab plasma concentration, FVIII inhibitor titre', 'and/or coagulation activity.', '3.3.5', 'Rationale for Pharmacokinetic Sample Collection Schedule', 'PK samples will be collected throughout the 2-year study period in order to further investigate', 'the PK of emicizumab (see the Schedule of Activities; Appendix 1', 'Schedule of Activities', ').', '3.3.6', 'Rationale for Immunogenicity Sample Collection', 'Immunogenicity will be monitored by investigating the incidence and clinical significance of', 'antibodies to emicizumab at specified time points (see the Schedule of Activities; Appendix 1', 'Schedule of Activities', '). The emergence of anti-drug antibodies (ADAs) has been previously observed in clinical', 'studies involving monoclonal antibodies of the IgG4 class (Lundkvist et al. 2012; Vennegoor', 'et al. 2013).', '3.3.7', 'Rationale for Disease Response-based Enpoints', 'The secondary objective of this study is to evaluate the efficacy of prophylactic', 'administration of emicizumab. This objective will be achieved by investigating the number of', 'bleeds over time under emicizumab treatment, assessing HRQoL, and evaluating health status', 'according to EQ-5D-5L and patient preference for the emicizumab regimen compared with the', 'previous regimen. As mentioned in Section 0, this analysis will occur when all patients have', 'completed 2 years of treatment or have withdrawn, whichever occurs sooner. In order to', 'obtain comprehensive data on each bleed, patients will be asked to report bleed information', 'on an ePRO device where possible, including site of bleed, type of bleed, time of each individual', 'bleed (day, start and stop time), and treatment for bleed.', 'Conducting the efficacy analysis after 2 years of therapy is supported by the results of', 'previous clinical studies that have demonstrated the benefits of long-term prophylactic', 'therapy in patients with hemophilia (Gringeri et al. 2011; Khawaji et al. 2012; Manco-', 'Johnson et al. 2007). The results of these studies showed that prophylactic treatment could', 'effectively prevent joint damage, decrease the frequency of joint and other hemorrhages,', \"and lead to improvements in the patients' HRQoL.\", '3.3.8', 'Rationale for Primary Enppoint Selection', 'As stated in Section 0, the primary objective of this study is to evaluate the overall safety and', 'tolerability of prophylactic administration of emicizumab. In order to achieve this objective,', 'the incidence and severity of all adverse events, including adverse events of special interest,', 'will be captured on an ongoing basis, as they occur during the study. Physical examinations,', 'vital signs, and laboratory values will be assessed as per the Schedule of Activities', '(Appendix 1', 'Schedule of Activities', 'Emicizumab - F. Hoffmann-La Roche Ltd', '107 / Protocol MO39129, Version 3'][').', 'The bypassing agents that are currently used for treating patients with hemophilia A are', 'associated with specific side effects, such as thromboembolic events, hypersensitivity', 'reactions, myocardial infarction, and disseminated intravascular coagulation (Bui et al. 2002;', 'Dentali et al. 2011; Tj\u00f8nnfjord 2004; W\u00f3jcik et al. 2009). In addition, these agents are', 'administered according to a frequent dosing schedule, which may reduce patient compliance', 'thereby making these regimens less effective and compromising their cost-benefit ratio', '(Thornburg 2010). Therefore, there currently exists an unmet need to develop novel', 'therapeutics for use in hemophilia A patients with inhibitors. This study will provide long-term', 'safety data on the prophylactic use of emicizumab.', '3.3.9', 'Rationale for Interim Analyses', 'Owing to the long-term nature of this study, interim analyses will be conducted in order to obtain', 'accurate information on the safety, efficacy, immunogenicity, and PK of prophylactic emicizumab at', 'specific points throughout the study. The first interim analysis will be performed once', 'approximately 100 patients have received treatment with emicizumab for at least 24 weeks. A', 'second interim analysis will be performed when approximately 100 patients have received', 'treatment with emicizumab for at least 52 weeks. The data from these analyses will', 'subsequently be presented to the iDMC in order to enable them to effectively monitor the', 'study.', '3.3.10', 'Rationale for Patient-reported Outcome (PRO) Assessments', 'During the study, electronic capture of HRQoL, health status (EQ-5D-5L) will be obtained', 'using an ePRO device. Patient preference data (EmiPref) will be collected on paper forms.', 'HRQoL is an important outcome in the care of patients with hemophilia (Brown et al. 2009).', 'HRQoL in hemophilic patients is multifaceted and is affected by disease symptoms (e.g.,', 'pain, bleeding), treatment (prophylactic, on demand, side effects), limitations on daily', 'functioning, anxiety / depression, and time spent in hospital.', 'The goal of measuring HRQoL is to quantify any treatment benefits from the patient', 'perspective. Previous studies that have used the Hemophilia Quality of Life questionnaire', '(Haemo-QoL), a measure of HRQoL parameters affected by hemophilia in children and', 'adolescents, have reported improvements in physical health, feelings, view of self, family', 'relations, friend relations, perceived support, relation with others, participation in sports,', 'dealing with hemophilia, views of treatment, views of the future, and relationships', '(Santagostino et al. 2014). Improvements in physical health, feelings, view of self, and', 'participation in work have also been observed on the adult version of the measure, the', 'Haem-A-Qol (Stasyshyn et al. 2014).', 'The HRQoL measures employed in the current study will be used to investigate the impact', 'of prophylactic administration of emicizumab in adolescents and adults with hemophilia A. In', 'addition, the measures will be used to evaluate the longitudinal changes in HRQoL with', 'emicizumab compared with the previous treatment regimen that the patients received.', 'The EQ-5D-5L is a standardized, preference-based measure of generic health status that is', 'applicable to a wide range of health conditions and treatments. It measures five dimensions', 'Emicizumab - F. Hoffmann-La Roche Ltd', '108 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}